| First Author | Qian Q | Year | 2019 |
| Journal | FASEB J | Volume | 33 |
| Issue | 3 | Pages | 4404-4417 |
| PubMed ID | 30576233 | Mgi Jnum | J:284806 |
| Mgi Id | MGI:6390421 | Doi | 10.1096/fj.201801846R |
| Citation | Qian Q, et al. (2019) Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer's disease. FASEB J 33(3):4404-4417 |
| abstractText | Alzheimer's disease (AD) is a leading cause of dementia. However, the mechanisms responsible for development of AD, especially for the sporadic variant, are still not clear. In our previous study, we discovered that a small noncoding RNA (miR-188-3p) targeting beta-site amyloid precursor protein cleaving enzyme (BACE)-1, a key enzyme responsible for Abeta formation, plays an important role in the development of neuropathology in AD. In the present study, we identified that miR-338-5p, a new miRNA that also targets BACE1, contributes to AD neuropathology. We observed that expression of miR-338-5p was significantly down-regulated in the hippocampus of patients with AD and 5XFAD transgenic (TG) mice, an animal model of AD. Overexpression of miR-338-5p in the hippocampus of TG mice reduced BACE1 expression, Abeta formation, and neuroinflammation. Overexpression of miR-338-5p functionally prevented impairments in long-term synaptic plasticity, learning ability, and memory retention in TG mice. In addition, we provide evidence that down-regulated expression of miR-338-5p in AD is regulated through the NF-kappaB signaling pathway. Our results suggest that down-regulated expression of miR-338-5p plays an important role in the development of AD.-Qian, Q., Zhang, J., He, F.-P., Bao, W.-X., Zheng, T.-T., Zhou, D.-M., Pan, H.-Y., Zhang, H., Zhang, X.-Q., He, X., Sun, B.-G., Luo, B.-Y., Chen, C., Peng, G.-P. Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer's disease. |
